Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
May 03, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc. Rhythm Pharmaceuticals, Inc. First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in adults and BMI-Z reductions in adolescents with Bardet-Biedl syndrome Delivered proof-of-concept data from Phase 2 Basket Study in HET POMC, PCSK1 or LEPR deficiencies, and obesity due to SRC1 and SH2B1 deficiencies Closed $172.5 million public offering and sold Priority Review Voucher for $100 million, providing additional funding to advance continued development of setmelanotide
Reitmans (Canada) Limited announces its results for the 13 and 52 weeks ended January 30, 2021
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
FBD reports €4 4m underwriting loss for 2020 following High Court ruling
farmersjournal.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from farmersjournal.ie Daily Mail and Mail on Sunday newspapers.